Cargando…

4CMenB Immunization Induces Serum Bactericidal Antibodies Against Non-Serogroup B Meningococcal Strains in Adolescents

INTRODUCTION: Invasive meningococcal disease (IMD) is an important public health concern. In developed countries, most IMD is caused by meningococcal serogroup B (MenB) and two protein-based MenB vaccines are currently available: the four-component vaccine 4CMenB (Bexsero, GSK) and the bivalent vacc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Biolchi, Alessia, Tomei, Sara, Brunelli, Brunella, Giuliani, Maria, Bambini, Stefania, Borrow, Ray, Claus, Heike, Gorla, Maria Cecilia O., Hong, Eva, Lemos, Ana Paula S., Lucidarme, Jay, Taha, Muhamed-Kheir, Vogel, Ulrich, Budroni, Sonia, Giuliani, Marzia M., Rappuoli, Rino, Boucher, Philip, Pizza, Mariagrazia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954916/ https://www.ncbi.nlm.nih.gov/pubmed/33185849 http://dx.doi.org/10.1007/s40121-020-00370-x

Ejemplares similares

Diversity of greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine
por: Tzanakaki, Georgina, et al.
Publicado: (2014)

Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules
por: Biolchi, Alessia, et al.
Publicado: (2019)

Does vaccination with 4CMenB convey protection against meningococcal serogroup B strains not predicted to be covered by MATS? A study of the UK clonal complex cc269
por: Stella, Maria, et al.
Publicado: (2019)

Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect
por: Ruiz García, Yara, et al.
Publicado: (2021)

7. Two-Dose 4CMenB Vaccination in Adolescents Elicits a Bactericidal Activity against 15 Outbreak-Representative Meningococcal Strains
por: Biolchi, Alessia, et al.
Publicado: (2020)

Genomic Characterization of Invasive Meningococcal Serogroup B Isolates and Estimation of 4CMenB Vaccine Coverage in Finland
por: Bodini, Margherita, et al.
Publicado: (2020)

OpcA and PorB are novel bactericidal antigens of the 4CMenB vaccine in mice and humans
por: Viviani, Viola, et al.
Publicado: (2023)

Cross-reactivity of 4CMenB vaccine-induced antibodies against meningococci belonging to non-B serogroups in Italy
por: Fazio, Cecilia, et al.
Publicado: (2021)

Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Portugal
por: Simões, Maria João, et al.
Publicado: (2017)

A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program
por: O’Ryan, Miguel, et al.
Publicado: (2013)

Meningococcal B Vaccination (4CMenB) in Infants and Toddlers
por: Esposito, Susanna, et al.
Publicado: (2015)

A re-assessment of 4CMenB vaccine effectiveness against serogroup B invasive meningococcal disease in England based on an incidence model
por: Argante, Lorenzo, et al.
Publicado: (2021)

High coverage of diverse invasive meningococcal serogroup B strains by the 4-component vaccine 4CMenB in Australia, 2007–2011: Concordant predictions between MATS and genetic MATS
por: Tozer, Sarah J., et al.
Publicado: (2021)

Culture-Confirmed Invasive Meningococcal Disease in Canada, 2010 to 2014: Characterization of Serogroup B Neisseria meningitidis Strains and Their Predicted Coverage by the 4CMenB Vaccine
por: Tsang, Raymond S. W., et al.
Publicado: (2020)

Safety and immunogenicity of co-administered meningococcal serogroup B (4CMenB) vaccine: A literature review
por: Abitbol, Véronique, et al.
Publicado: (2023)

Progressive Decrease in the Potential Usefulness of Meningococcal Serogroup B Vaccine (4CMenB, Bexsero®) in Gipuzkoa, Northern Spain
por: Pérez-Trallero, Emilio, et al.
Publicado: (2014)

Immunological fingerprint of 4CMenB recombinant antigens via protein microarray reveals key immunosignatures correlating with bactericidal activity
por: Bartolini, E., et al.
Publicado: (2020)

Characterization of meningococcal carriage isolates from Greece by whole genome sequencing: Implications for 4CMenB vaccine implementation
por: Kesanopoulos, Konstantinos, et al.
Publicado: (2018)

Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B Neisseria meningitidis Isolated from 2009 to 2013 in the Republic of Ireland
por: Mulhall, Robert M., et al.
Publicado: (2018)

The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae
por: Leduc, Isabelle, et al.
Publicado: (2020)

Multicomponent meningococcal B vaccination (4CMenB) of adolescents and college students in the United States
por: Banzhoff, Angelika
Publicado: (2017)

Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease
por: Scholz, Stefan, et al.
Publicado: (2021)

4CMenB vaccine induces elite cross-protective human antibodies that compete with human factor H for binding to meningococcal fHbp
por: Veggi, Daniele, et al.
Publicado: (2020)

Predicted Strain Coverage of a New Meningococcal Multicomponent Vaccine (4CMenB) in Spain: Analysis of the Differences with Other European Countries
por: Abad, Raquel, et al.
Publicado: (2016)

B Part of It School Leaver protocol: an observational repeat cross-sectional study to assess the impact of a meningococcal serogroup B (4CMenB) vaccine programme on carriage of Neisseria meningitidis
por: Marshall, Helen S, et al.
Publicado: (2019)

Correction to: Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease
por: Scholz, Stefan, et al.
Publicado: (2022)

Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England
por: Ladhani, Shamez N., et al.
Publicado: (2016)

Persistence of Bactericidal Activity at 4 Years After 2 Primary Doses of a Recombinant, 4-Component, Meningococcal Serogroup B Vaccine (4CMenB) and Response to a Booster Dose in Adolescents and Young Adults
por: Nolan, Terry, et al.
Publicado: (2017)

Molecular characterization of invasive Neisseria meningitidis isolates collected in Lithuania (2009-2019) and estimation of serogroup B meningococcal vaccine 4CMenB and MenB-Fhbp coverage
por: Sereikaitė, Emilija, et al.
Publicado: (2023)

Genomic Surveillance of 4CMenB Vaccine Antigenic Variants among Disease-Causing Neisseria meningitidis Isolates, United Kingdom, 2010–2016
por: Rodrigues, Charlene M.C., et al.
Publicado: (2018)

Genomic resolution of an aggressive, widespread, diverse and expanding meningococcal serogroup B, C and W lineage
por: Lucidarme, Jay, et al.
Publicado: (2015)

Does social deprivation correlate with meningococcal MenACWY, Hib/MenC and 4CMenB/Meningococcal Group B vaccine uptake in Northern Ireland?
por: Brennan, Orlaith C., et al.
Publicado: (2022)

02. Beyond B Antigen Coverage: The Potential of the 4CMenB Vaccine for Cross-protection Against Pathogenic Neisseria Infections
por: Garcia, Yara Ruiz, et al.
Publicado: (2021)

Evaluating the effectiveness of the 4CMenB vaccine against invasive meningococcal disease and gonorrhoea in an infant, child and adolescent program: protocol
por: Marshall, Helen S., et al.
Publicado: (2021)

Exploiting Real-Time Genomic Surveillance Data To Assess 4CMenB Meningococcal Vaccine Performance in Scotland, 2015 to 2022
por: Rodrigues, C. M. C., et al.
Publicado: (2023)

Adverse events following immunisation with four-component meningococcal serogroup B vaccine (4CMenB): interaction with co-administration of routine infant vaccines and risk of recurrence in European randomised controlled trials
por: Zafack, Joseline Guetsop, et al.
Publicado: (2019)

An open-label randomised controlled trial evaluating the efficacy of a meningococcal serogroup B (4CMenB) vaccine on Neisseria gonorrhoeae infection in gay and bisexual men: the MenGO study protocol
por: Thng, Caroline, et al.
Publicado: (2023)

Fever-Associated Supraventricular Tachycardia after 4CMenB Vaccination in an Infant
por: Gönüllü, Erdem, et al.
Publicado: (2019)

An Observational Study to Assess the Effectiveness of 4CMenB against Meningococcal Disease and Carriage and Gonorrhea in Adolescents in the Northern Territory, Australia—Study Protocol
por: Marshall, Helen S., et al.
Publicado: (2022)

Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine
por: McNeil, Lisa K., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2bluis1o36l9q3ulsnskclcg8k